Study guide

3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship

Australian Dental Council ADC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Examination Overview

1.1 ADC Written Examination Structure, Scoring Clusters & Australian Practice Context 1.2 Clinical Scenario Reasoning & Australian Therapeutic Guidelines Alignment

2 Chapter 2: Restorative Dentistry & Fixed Prosthodontics

2.1 Minimal Intervention Dentistry, Caries Risk & Lesion Management 2.2 Direct Restorative Materials, Resin Composites & Dental Amalgam 2.3 Indirect Restorations, Crown Preparation, Veneers & Onlays 2.4 Dental Adhesion, Etch-and-Rinse vs Self-Etch Systems & Hybrid Layer 2.5 Diagnosis & Management of Tooth Wear (Erosion, Attrition, Abrasion, Abfraction)

3 Chapter 3: Dental Pharmacology & Therapeutic Guidelines

3.1 Local Anaesthetic Agents, Vasoconstrictors & Injection Techniques 3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship 3.3 Dental Antibiotic Prescribing, Prophylaxis & Therapeutic Guidelines 3.4 Management of Patients on Anticoagulants & Antiplatelet Therapy 3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management

4 Chapter 4: General Medicine & Medically Compromised Patients

4.1 Dental Office Medical Emergencies, Anaphylaxis & Resuscitation Protocols 4.2 Management of Patients with Cardiovascular, Respiratory & Renal Diseases 4.3 Special Needs Dentistry, Geriatric Care & Dental Management in Pregnancy 4.4 Infective Endocarditis Prophylaxis & Cardiac Risk Assessment

5 Chapter 5: Oral Medicine & Oral Pathology

5.1 Ulcerative, Vesiculobullous & Immune-Mediated Oral Mucosal Diseases 5.2 Oral Potentially Malignant Disorders (OPMDs) & Oral Cancer Screening 5.3 Salivary Gland Disorders, Sialadenitis & Cysts of the Jaws 5.4 Oral Biopsy Indications, Diagnostic Pathways & Specialist Referral

6 Chapter 6: Endodontics

6.1 Pulpal and Periapical Diagnostic Classification & Diagnostic Testing 6.2 Canal Instrumentation, Working Length & Irrigation Protocols 6.3 Root Canal Obturation, Endodontic Retreatment & Failure Analysis 6.4 Endodontic Management of Traumatic Dental Injuries & Vital Pulp Therapy

7 Chapter 7: Oral Surgery

7.1 Surgical & Simple Exodontia Techniques & Intraoperative Complications 7.2 Assessment & Surgical Management of Impacted Third Molars 7.3 Oroantral Communication, Displacement & Trigeminal Nerve Injury Prevention 7.4 Management of Spreading Odontogenic Infections & Fascial Space Abscesses

8 Chapter 8: Paediatric Dentistry & Orthodontics

8.1 Primary Tooth Pulpotomy, Pulpectomy & Stainless Steel Crown Restoration 8.2 Early Childhood Caries, Space Maintenance & Traumatic Primary Dentition 8.3 Malocclusion Classification, Etiology & Interceptive Orthodontic Management 8.4 Non-Pharmacological Behaviour Guidance, Child Protection & Consent

9 Chapter 9: Periodontics

9.1 2018 Periodontal Staging, Grading & Risk Factor Assessment 9.2 Subgingival Debridement, Plaque Control & Antimicrobial Adjuncts 9.3 Periodontal Surgical Flaps, Regenerative Therapy & Furcation Management 9.4 Supportive Periodontal Care, Maintenance Protocols & Risk Re-evaluation

10 Chapter 10: Preventive Dentistry

10.1 Caries Risk Assessment Models (CAMBRA) & Personalised Prevention 10.2 Fluoride Mechanisms, Topical Applications & Community Fluoridation 10.3 Dietary Counselling, Stephan Curve Dynamics & Erosion Prevention 10.4 Pit and Fissure Sealants, Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)

11 Chapter 11: Dental Emergencies

11.1 Emergency Management of Severe Odontogenic Pain & Acute Irreversible Pulpitis 11.2 Acute Management of Avulsed, Luxated & Fractured Permanent Teeth 11.3 Diagnosis, Differentiation & Treatment of Cracked Tooth Syndrome 11.4 Emergency Management of Post-Extraction Hemorrhage & Acute Abscesses

12 Chapter 12: Pain & Behaviour Management

12.1 Assessment & Management of Dental Anxiety, Phobia & Dental Fear 12.2 Nitrous Oxide Inhalation Sedation & Intravenous Sedation Guidelines 12.3 Diagnosis & Management of Temporomandibular Disorders & Chronic Facial Pain 12.4 Informed Consent, Patient Autonomy, Ethics & Professional Boundaries

13 Chapter 13: Removable Prosthodontics

13.1 Complete Denture Design, Impression Techniques & Maxillomandibular Relations 13.2 Removable Partial Denture Design, Surveying, Clasping & RPI System 13.3 Post-Insertion Problems, Sore Spots, Relining & Rebase Procedures 13.4 Denture Stomatitis, Tissue Conditioning & Pre-Prosthetic Surgery

14 Chapter 14: Dental Radiography & Imaging

14.1 Radiation Physics, ALARA Principles, Shielding & Dose Reduction 14.2 Intraoral Radiographic Techniques, Positioning & Geometry 14.3 Radiographic Interpretation, Normal Anatomical Landmarks & Artifacts

15 Chapter 15: Infection Prevention & Control

15.1 Standard & Transmission-Based Precautions in Dental Practice 15.2 Instrument Reprocessing, Autoclaving & Sterilisation Monitoring 15.3 Dental Unit Waterlines, Waste Management & Occupational Exposure Protocols

16 Chapter 16: Dental Implants & Peri-Implant Diseases

16.1 Patient Selection, Bone Density, Anatomic Constraints & Prosthetic Planning 16.2 Peri-Implant Anatomy, Hygiene Protocols & Maintenance Monitoring 16.3 Diagnosis, Risk Factors & Management of Peri-Implant Diseases

3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship

Key Takeaways Explain This Topic AI

First-line management of inflammatory acute dental pain relies on non-steroidal anti-inflammatory drugs (NSAIDs), specifically Ibuprofen 400 mg taken every 6 hours.

Combining Ibuprofen (400 mg) and Paracetamol (1000 mg) provides superior analgesic efficacy compared to standard doses of codeine or oxycodone combinations.

Maximum daily dose of Paracetamol in adults is 4000 mg (4 g) per 24 hours to prevent severe hepatotoxicity; lower caps apply in chronic liver disease or alcohol dependence.

NSAIDs are contraindicated in severe renal impairment (eGFR <30 mL/min), active peptic ulcer disease, third-trimester pregnancy, severe heart failure, and aspirin-exacerbated respiratory disease.

Opioids are non-first-line agents in dentistry; codeine combination products were rescheduled to Schedule 4 (Prescription Only) in Australia due to risks of variable CYP2D6 metabolism and addiction.

Last updated: August 2026

3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship

Effective management of acute dental pain requires a thorough understanding of the inflammatory cascade, peripheral and central pain sensitization, and evidence-based pharmacotherapy aligned with Therapeutic Guidelines: Dental (eTG). Modern Australian dental practice prioritises non-opioid multimodal analgesia while restricting opioid use through strict antimicrobial and opioid stewardship principles.

Neurophysiology of Inflammatory Dental Pain

Dental pain arising from pulpal inflammation, periapical periodontitis, or surgical trauma is predominantly inflammatory nociceptive pain . Tissue injury triggers the release of membrane phospholipids, which are converted by phospholipase A 2 A_2 A 2 ​ into arachidonic acid. +---------------------------------------------------------------------------------------------------+

  • | INFLAMMATORY PAIN CASCADE |
  • | |
  • | Cell Membrane Phospholipids ==[Phospholipase A2]==> Arachidonic Acid |
  • | || |
  • | +[COX-1 / COX-2 Enzymes]+ |
  • | || |
  • | / |
  • | Prostaglandins (PGE2, PGI2) |
  • | || |
  • | / |
  • | Sensitization of Peripheral Nociceptors |
  • +---------------------------------------------------------------------------------------------------+

Prostaglandin E 2 E_2 E 2 ​ ( P G E 2 PGE_2 PG E 2 ​ ) and Prostacyclin ( P G I 2 PGI_2 PG I 2 ​ ) sensitise peripheral free nerve endings ( A δ A\delta A δ and C C C nociceptors) to chemical mediators such as bradykinin, histamine, and substance P, lowering the activation threshold for pain impulses transmitted to the central nervous system.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs act by competitively inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby blocking the synthesis of pro-inflammatory prostaglandins.

COX-1 Enzyme : Constitutively expressed in stomach mucosa, renal parenchyma, and platelets. Mediates gastric cytoprotection (via P G E 2 PGE_2 PG E 2 ​ ), renal blood flow autoregulation, and platelet aggregation (via Thromboxane A 2 A_2 A 2 ​ ).

COX-2 Enzyme : Inducible isoform expressed predominantly at sites of tissue inflammation, pain, and cellular injury.

Non-Selective vs. COX-2 Selective NSAIDs

Parameter Ibuprofen Naproxen Celecoxib

Mechanism Non-selective COX-1 & COX-2 inhibitor Non-selective COX-1 & COX-2 inhibitor Highly selective COX-2 inhibitor

Standard Dental Dose 400 mg q6h (Max 2400 mg/day) 250 – 500 mg bd (Max 1250 mg/day) 100 – 200 mg daily (Max 400 mg/day)

  • Onset of Analgesia 30 – 60 minutes 1 – 2 hours 60 minutes
  • GI Ulcer Risk Moderate Moderate Reduced compared to non-selective
  • Cardiovascular Risk Low at standard doses Lowest CV risk among NSAIDs Elevated in high-risk CV patients
  • Primary Indications in Dental Practice

NSAIDs represent the first-line pharmacological agent for acute dental pain (e.g., pulpitis, post-extraction pain, surgical endodontic pain) because they target the primary peripheral inflammatory cause of nociception.

Paracetamol (Acetaminophen) Pharmacokinetics & Synergy

Paracetamol is an effective analgesic and antipyretic with weak peripheral anti-inflammatory action. Its precise mechanism involves central inhibition of prostaglandin synthesis, action on central serotonergic pathways, and interaction with the endocannabinoid system ( A M 404 AM404 A M 404 active metabolite).

Adult Dosing Guidelines (eTG Dental)

Standard Adult Dose : 500 mg to 1000 mg orally every 4 to 6 hours as required.

Maximum Daily Limit : 4000 mg (4 g) in 24 hours for adults > 50 kg >50\text{ kg} > 50 kg .

Hepatic Compromise / Chronic Alcoholism Limit : Capped at 2000 mg (2 g) in 24 hours to avoid accumulation of N N N -acetyl- p p p -benzoquinone imine ( N A P Q I NAPQI N A PQ I ), the toxic metabolite responsible for acute hepatic necrosis.

The Multimodal Synergistic Protocol

Clinical trials consistently demonstrate that combining a non-selective NSAID with Paracetamol produces superior pain relief than either agent alone, achieving an efficacy superior to standard oral opioid regimens (e.g., Codeine 60 mg or Oxycodone 5 mg). MULTIMODAL DENTAL ANALGESIC REGIMEN:

-------------------------------------------------------------------------------------

Take TOGETHER every 6 hours:

  • > Ibuprofen 400 mg ORALLY
  • > Paracetamol 1000 mg ORALLY
  • ------------------------------------------------------------------------------------
  • Clinical Benefit: Dual peripheral (NSAID) and central (Paracetamol) pain inhibition

without increasing opioid-related adverse effects.

Stepped Dental Analgesia Protocols (Therapeutic Guidelines: Dental)

Australian dental practice follows a clear stepped protocol tailored to severity of expected or presenting pain: +---------------------------------------------------------------------------------------------------+

  • | STEPPED DENTAL ANALGESIC LADDER |
  • | |
  • | STEP 1: Mild Pain =======> Paracetamol 1000 mg q6h OR Ibuprofen 400 mg q6h |
  • | |
  • | STEP 2: Moderate Pain =======> Paracetamol 1000 mg PLUS Ibuprofen 400 mg TOGETHER q6h |
  • | |
  • | STEP 3: Severe Pain =======> Paracetamol 1000 mg + Ibuprofen 400 mg q6h |
  • | PLUS Short-Course Oxycodone 5 mg q6h (Max 2-3 days) |
  • +---------------------------------------------------------------------------------------------------+
  • Summary Table of Analgesic Protocols
  • Severity Primary Regimen Alternative (If NSAID Contraindicated)
  • Mild Pain Ibuprofen 200–400 mg q6h prn Paracetamol 500–1000 mg q4–6h prn
  • Moderate Pain Ibuprofen 400 mg + Paracetamol 1000 mg q6h Paracetamol 1000 mg q6h + Celecoxib 200 mg daily

Severe Acute Pain Ibuprofen 400 mg + Paracetamol 1000 mg q6h + Oxycodone 5 mg q6h (max 8-10 tabs total) Paracetamol 1000 mg q6h + Oxycodone 5 mg q6h (strict 48-72h limit)

  • Contraindications, Precautions & Organ System Toxicity
  • NSAID Organ Toxicity Profile

Gastrointestinal Toxicity : Inhibition of COX-1 reduces protective gastric mucosal mucus and bicarbonate secretion. Risk factors include age > 65 >65 > 65 , history of peptic ulcer disease, concurrent systemic corticosteroid use, and concomitant anticoagulant therapy.

Renal Impairment : Prostaglandins ( P G E 2 PGE_2 PG E 2 ​ , P G I 2 PGI_2 PG I 2 ​ ) maintain renal arteriolar vasodilation. NSAID administration in patients with compromised volume status or pre-existing renal disease can cause acute kidney injury (AKI) via afferent arteriolar constriction. Contraindicated if eGFR < 30 mL/min/1.73 m 2 \text{eGFR} < 30\text{ mL/min/1.73 m}^2 eGFR < 30 mL/min/1.73 m 2 .

Cardiovascular Disease : Non-selective NSAIDs (except Naproxen) and COX-2 inhibitors impair endothelial P G I 2 PGI_2 PG I 2 ​ production while sparing platelet T X A 2 TXA_2 TX A 2 ​ , promoting thrombosis. Contraindicated in severe heart failure (NYHA Class III/IV) and recent coronary artery bypass graft (CABG) surgery.

Pregnancy Considerations : NSAIDs are strictly contraindicated in the third trimester due to premature closure of the fetal ductus arteriosus and inhibition of uterine contractions leading to delayed labor.

Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad) : Triad of asthma, nasal polyposis, and aspirin/NSAID hypersensitivity. COX-1 inhibition shunts arachidonic acid metabolism down the 5-lipoxygenase pathway, driving massive cysteinyl leukotriene release and life-threatening bronchospasm.

Opioid Stewardship in Australian Dental Practice

In February 2018, the Therapeutic Goods Administration (TGA) rescheduled all over-the-counter codeine combination analgesics to Schedule 4 (Prescription Only) due to growing rates of misuse, dependence, and organ toxicity.

Pharmacogenomics of Codeine

Codeine is a prodrug requiring bioactivation to morphine via the hepatic enzyme CYP2D6 .

Poor Metabolisers (~6-10% of Caucasians): Possess non-functional CYP2D6 alleles and experience negligible analgesia.

Ultra-Rapid Metabolisers (~1-7% of population, higher in North African and Middle Eastern ethnicities): Possess gene duplications resulting in rapid conversion to morphine, predisposing patients to potentially fatal respiratory depression even at standard doses.

Australian Guidelines on Dental Opioid Prescribing

Opioids must never be prescribed as routine first-line therapy for dental pain.

Indications are restricted to acute, severe pain refractory to maximal doses of Paracetamol and NSAIDs, or where NSAIDs are absolute contraindications.

Prescription quantity must be limited to no more than 2 to 3 days supply (maximum 8–10 capsules/tablets of immediate-release Oxycodone 5 mg).

Modified-release (sustained-release) opioid preparations are strictly prohibited for acute dental pain management.

Loading diagram... Inflammatory Arachidonic Acid Cascade and Pharmacological Targets